Opto B Discovery on the Beacon® platform revolutionizes antibody discovery (AbD) with its function-first, high-throughput single B cell screening, maximizing the success of your antibody campaigns.
By conducting multiple functional assays, including antigen specificity, affinity, cross-reactivity, cell-based functions, and blocking assays, on tens of thousands of cells in a single run, the Beacon platform delivers the highest level of characterization for each single cell.
The Opto B Discovery workflows on the Beacon platform provides an unparalleled, efficient, and reliable solution for antibody discovery, ensuring your success with both easy and challenging targets.
Revolutionizing Antibody Discovery
of Antibody Discovery with the Beacon Platform
Conduct up to 16 functional assays, including antigen specificity, affinity, cross-reactivity, ligand blocking, internalization, and cell-based function, on up to 60,000 B cells per run, generating up to 1 million data points and maximizing antibody characterization. Empower artificial intelligence (AI)-based antibody discovery by leveraging the rich, high-parameter data generated by the Beacon platform to train data-hungry AI models.
Optimize your antibody discovery process with the innovative Opto® B Discovery Affinity Assay. This cutting-edge tool allows researchers to rapidly rank antibody hits based on relative affinity, enhancing the selection of top candidates early in the discovery process.
Screen antibodies across diverse species (human, mouse, rabbit, alpaca, and more), organ types (spleen, bone marrow, lymph nodes, and peripheral blood) and cell types (plasma and memory B cells), resulting in diverse antibody hits with even the most challenging targets, including multi-transmembrane proteins, targets with high host homology, and low immunogenicity antigens.
Diverse Host Species
for Challenging Targets
Empower screening with small-volume samples and customizable assays suitable for therapeutic antibodies in any disease area. Optofluidics are ideal for small or precious human samples (as few as a single patient draw) and enable broad applications, ranging from vaccine development for infectious diseases, discovering autoantibodies responsible for autoimmune disorders, and identifying novel antibodies against tumor-associated antigens (TAAs) for oncology.
